146 related articles for article (PubMed ID: 37611150)
1. Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.
Pinheiro M; Peixoto A; Rocha P; Santos C; Escudeiro C; Veiga I; Porto M; Guerra J; Barbosa A; Pinto C; Arinto P; Resende A; Teixeira MR
Pharmacogenet Genomics; 2023 Oct; 33(8):165-171. PubMed ID: 37611150
[TBL] [Abstract][Full Text] [Related]
2. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
3.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
[TBL] [Abstract][Full Text] [Related]
4. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
[TBL] [Abstract][Full Text] [Related]
6. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
[TBL] [Abstract][Full Text] [Related]
7. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
8. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R
Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313
[TBL] [Abstract][Full Text] [Related]
9. Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Miarons M; Manzaneque Gordón A; Riera P; Gutiérrez Nicolás F;
Oncologist; 2023 May; 28(5):e304-e308. PubMed ID: 37014829
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
[TBL] [Abstract][Full Text] [Related]
11. Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
Wong BYL; Li Z; Raphael MJ; De Angelis C; Hwang DM; Fu L
J Appl Lab Med; 2024 Mar; 9(2):295-304. PubMed ID: 38084968
[TBL] [Abstract][Full Text] [Related]
12. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
[TBL] [Abstract][Full Text] [Related]
13. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
[TBL] [Abstract][Full Text] [Related]
15. Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.
Riera P; Riba M; Bernal S; Virgili AC; Páez D; Moreno ME
Farm Hosp; 2021 Dec; 45(7):5-10. PubMed ID: 35379107
[TBL] [Abstract][Full Text] [Related]
16. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
19. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
Medwid S; Wigle TJ; Kim RB
Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
[TBL] [Abstract][Full Text] [Related]
20. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
